Treats active duodenal ulcer. ANDA 208671, held by Macleods Pharmaceuticals. Lansoprazole.
As of Nov 21, 2026, ANDA 208671 (Lansoprazole), held by Macleods Pharmaceuticals, was first approved by FDA on Nov 4, 2024, with 0 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release capsules, are a proton pump inhibitors (PPIs) indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 4, 2024 | Original application | Approved | None posted |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters